BCRP Inhibition: from Data Collection to Ligand‐Based Modeling

Breast Cancer Resistance Protein (BCRP, gene ABCG2) is an efflux transporter from the ABC transporters family. It is known to be responsible for the multidrug resistance phenomenon observed in some cancers and is also involved in drug‐drug interactions in the liver. Prediction and assessment of inhibition of BCRP is of great interest in the drug development process. This paper presents the largest open dataset currently available for BCRP inhibition, along with the methodology used to compile it. It contains 978 unique compounds with corresponding bioactivities, extracted from 47 studies. The presence of duplicates allowed us to set up thresholds on reported activities to obtain a labelled dataset suitable for learning classification models. Exploratory data analysis and predictive modelling lead to the identification of substructures important for inhibition. We find that the substructures that characterize inhibitors are in line with known SAR relationships of BCRP inhibitors, while the substructures characterizing the non‐inhibitors are novel.

[1]  Michael Dean,et al.  New inhibitors of ABCG2 identified by high-throughput screening , 2007, Molecular Cancer Therapeutics.

[2]  Qingcheng Mao,et al.  Role of the breast cancer resistance protein (ABCG2) in drug transport , 2005, The AAPS Journal.

[3]  E. LaVoie,et al.  Synthesis of N-substituted 5-[2-(N-alkylamino)ethyl]dibenzo[c,h][1,6]naphthyridines as novel topoisomerase I-targeting antitumor agents. , 2008, Bioorganic & medicinal chemistry.

[4]  Francesca Borrelli,et al.  Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors. , 2007, Journal of medicinal chemistry.

[5]  Marilyn E. Morris,et al.  Structure–Activity Relationships and Quantitative Structure–Activity Relationships for Breast Cancer Resistance Protein (ABCG2) , 2009, The AAPS Journal.

[6]  Sean Ekins,et al.  Precompetitive preclinical ADME/Tox data: set it free on the web to facilitate computational model building and assist drug development. , 2010, Lab on a chip.

[7]  Michael Wiese,et al.  Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). , 2011, Bioorganic & medicinal chemistry.

[8]  C. Hrycyna,et al.  Multidrug resistance and cancer: the role of the human ABC transporter ABCG2. , 2002, Current protein & peptide science.

[9]  S. Hladky,et al.  Interaction of the breast cancer resistance protein with plant polyphenols. , 2004, Biochemical and biophysical research communications.

[10]  X. Ronot,et al.  Piperazinobenzopyranones and phenalkylaminobenzopyranones: potent inhibitors of breast cancer resistance protein (ABCG2). , 2005, Journal of medicinal chemistry.

[11]  Guidance for Industry Drug Interaction Studies — Study Design , Data Analysis , Implications for Dosing , and Labeling Recommendations , 2022 .

[12]  Ulf Norinder,et al.  Identification of Novel Specific and General Inhibitors of the Three Major Human ATP-Binding Cassette Transporters P-gp, BCRP and MRP2 Among Registered Drugs , 2009, Pharmaceutical Research.

[13]  T. Litman,et al.  Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. , 1999, Cancer research.

[14]  F. Berardi,et al.  Synthesis and biological evaluation of (hetero)arylmethyloxy- and arylmethylamine-phenyl derivatives as potent P-glycoprotein modulating agents. , 2008, Journal of medicinal chemistry.

[15]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  T. Ishikawa,et al.  Cellular Phototoxicity Evoked Through the Inhibition of Human ABC Transporter ABCG2 by Cyclin-dependent Kinase Inhibitors In vitro , 2009, Pharmaceutical Research.

[17]  A. Buschauer,et al.  Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2). , 2011, Bioorganic & medicinal chemistry letters.

[18]  Veronika F. S. Pape,et al.  Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein. , 2012, Bioorganic & medicinal chemistry.

[19]  Tingjun Hou,et al.  New Use for an Old Drug: Inhibiting ABCG2 with Sorafenib , 2012, Molecular Cancer Therapeutics.

[20]  Ulf Norinder,et al.  A Global Drug Inhibition Pattern for the Human ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (ABCG2) , 2007, Journal of Pharmacology and Experimental Therapeutics.

[21]  H. V. van Veen,et al.  Metabolites of ginsenosides as novel BCRP inhibitors. , 2006, Biochemical and biophysical research communications.

[22]  M. Morris,et al.  Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. , 2004, Molecular pharmacology.

[23]  W. Haefeli,et al.  Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. , 2006, The Journal of antimicrobial chemotherapy.

[24]  G. Giannini,et al.  E-ring-modified 7-oxyiminomethyl camptothecins: Synthesis and preliminary in vitro and in vivo biological evaluation. , 2008, Bioorganic & medicinal chemistry letters.

[25]  W. Haefeli,et al.  Interaction Potential of Etravirine with Drug Transporters Assessed In Vitro , 2010, Antimicrobial Agents and Chemotherapy.

[26]  A. Tropsha,et al.  Human Intestinal Transporter Database: QSAR Modeling and Virtual Profiling of Drug Uptake, Efflux and Interactions , 2013, Pharmaceutical Research.

[27]  A. di Pietro,et al.  Potent and fully noncompetitive peptidomimetic inhibitor of multidrug resistance P-glycoprotein. , 2010, Journal of medicinal chemistry.

[28]  Á. Ravelo,et al.  Bis-pyranobenzoquinones as a new family of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in mammalian cells and the protozoan parasite Leishmania. , 2008, Journal of medicinal chemistry.

[29]  Y. Sugimoto,et al.  Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure–activity relationship , 2007, Cancer Chemotherapy and Pharmacology.

[30]  Vincenzo,et al.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. , 1998, Cancer research.

[31]  M. Go,et al.  Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein. , 2008, Bioorganic & medicinal chemistry.

[32]  Curtis J Henrich,et al.  Flavonoids from eight tropical plant species that inhibit the multidrug resistance transporter ABCG2. , 2011, Journal of natural products.

[33]  Y. Sugimoto,et al.  Phytoestrogens/Flavonoids Reverse Breast Cancer Resistance Protein/ABCG2-Mediated Multidrug Resistance , 2004, Cancer Research.

[34]  Stephan Kopp,et al.  Multispecificity of Drug Transporters: Probing Inhibitor Selectivity for the Human Drug Efflux Transporters ABCB1 and ABCG2 , 2007, ChemMedChem.

[35]  Peter W Swaan,et al.  Identification of novel breast cancer resistance protein (BCRP) inhibitors by virtual screening. , 2013, Molecular pharmaceutics.

[36]  Hikaru Saito,et al.  Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer. , 2006, Cancer letters.

[37]  J. Allen,et al.  Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines. , 2001, Bioorganic & medicinal chemistry letters.

[38]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[39]  Julien Boccard,et al.  Breast cancer resistance protein (BCRP/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[40]  J. Allen,et al.  The multidrug transporter ABCG2 (BCRP) is inhibited by plant‐derived cannabinoids , 2007, British journal of pharmacology.

[41]  T. Ishikawa,et al.  Novel camptothecin analogues that circumvent ABCG2‐associated drug resistance in human tumor cells , 2004, International journal of cancer.

[42]  M. Wiese,et al.  Synthesis and Quantitative Structure–Activity Relationships of Selective BCRP Inhibitors , 2013, ChemMedChem.

[43]  Shuzhong Zhang,et al.  Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. , 2005, Biochemical pharmacology.

[44]  Michael Wiese,et al.  Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). , 2008, Bioorganic & medicinal chemistry.

[45]  T. Tsuruo,et al.  Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. , 2003, Molecular cancer therapeutics.

[46]  Francisco Gamarro,et al.  Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. , 2005, Cancer research.

[47]  J. Donovan,et al.  Antipsychotic drugs inhibit the function of breast cancer resistance protein. , 2008, Basic & clinical pharmacology & toxicology.

[48]  M. Wiese,et al.  Novel lead for potent inhibitors of breast cancer resistance protein (BCRP). , 2010, Bioorganic & medicinal chemistry letters.

[49]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[50]  M. Wiese,et al.  4-Substituted-2-phenylquinazolines as inhibitors of BCRP. , 2012, Bioorganic & medicinal chemistry letters.

[51]  Pekka Tiikkainen,et al.  Estimating Error Rates in Bioactivity Databases , 2013, J. Chem. Inf. Model..

[52]  Zhe-Sheng Chen,et al.  Inhibition of c-Kit, VEGFR-2 (KDR), and ABCG2 by analogues of OSI-930. , 2011, Bioorganic & medicinal chemistry letters.

[53]  A. di Pietro,et al.  Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2. , 2007, Bioorganic & medicinal chemistry.

[54]  Hiroyuki Hirano,et al.  A New Strategy of High-Speed Screening and Quantitative Structure-Activity Relationship Analysis to Evaluate Human ATP-Binding Cassette Transporter ABCG2-Drug Interactions , 2006, Journal of Pharmacology and Experimental Therapeutics.

[55]  K. Gustafson,et al.  Synthesis and structure-activity relationship of botryllamides that block the ABCG2 multidrug transporter. , 2010, Bioorganic & medicinal chemistry letters.

[56]  F. Berardi,et al.  2-[(3-Methoxyphenylethyl)phenoxy]-based ABCB1 inhibitors: effect of different basic side-chains on their biological properties. , 2008, Journal of medicinal chemistry.

[57]  E. LaVoie,et al.  12-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridines as novel topoisomerase I-targeting antitumor agents. , 2009, Bioorganic & medicinal chemistry.

[58]  Christin Müller,et al.  Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. , 2009, Journal of medicinal chemistry.